These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 10394021)
1. The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Amantea MA; Bowden RA; Forrest A; Working PK; Newman MS; Mamelok RD Chemotherapy; 1999 Jun; 45 Suppl 1():48-53. PubMed ID: 10394021 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Amantea MA; Bowden RA; Forrest A; Working PK; Newman MS; Mamelok RD Antimicrob Agents Chemother; 1995 Sep; 39(9):2042-7. PubMed ID: 8540713 [TBL] [Abstract][Full Text] [Related]
3. Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients. Gurwith M; Mamelok R; Pietrelli L; Du Mond C Chemotherapy; 1999 Jun; 45 Suppl 1():39-47. PubMed ID: 10394020 [TBL] [Abstract][Full Text] [Related]
4. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Noskin G; Pietrelli L; Gurwith M; Bowden R Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Bowden RA; Cays M; Gooley T; Mamelok RD; van Burik JA J Infect Dis; 1996 May; 173(5):1208-15. PubMed ID: 8627074 [TBL] [Abstract][Full Text] [Related]
6. Experience with liposomal amphotericin B at the Hematology-Oncology Department Children's Hospital Salata Medical School, University of Zagreb. Konja J; Glavas B; Anicić M Acta Biomed; 2006; 77 Suppl 2():14-6. PubMed ID: 16918061 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Wingard JR Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244 [TBL] [Abstract][Full Text] [Related]
8. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Anaissie EJ; Mattiuzzi GN; Miller CB; Noskin GA; Gurwith MJ; Mamelok RD; Pietrelli LA Antimicrob Agents Chemother; 1998 Mar; 42(3):606-11. PubMed ID: 9517940 [TBL] [Abstract][Full Text] [Related]
9. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections. Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482 [TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections? Schneemann M; Bachli EB Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468 [No Abstract] [Full Text] [Related]
12. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206 [TBL] [Abstract][Full Text] [Related]
13. Safety of amphotericin B colloidal dispersion. Herbrecht R Eur J Clin Microbiol Infect Dis; 1997 Jan; 16(1):74-80. PubMed ID: 9063677 [TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. White MH; Bowden RA; Sandler ES; Graham ML; Noskin GA; Wingard JR; Goldman M; van Burik JA; McCabe A; Lin JS; Gurwith M; Miller CB Clin Infect Dis; 1998 Aug; 27(2):296-302. PubMed ID: 9709879 [TBL] [Abstract][Full Text] [Related]
16. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
17. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. Altmannsberger P; Holler E; Andreesen R; Krause SW J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868 [No Abstract] [Full Text] [Related]
18. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections]. Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521 [TBL] [Abstract][Full Text] [Related]
19. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072 [TBL] [Abstract][Full Text] [Related]
20. Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion. Beović B; Lejko-Zupanc T; Pretnar J Eur J Clin Microbiol Infect Dis; 1997 Jul; 16(7):507-11. PubMed ID: 9272385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]